Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options
Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study
Excerpt from the Press Release:
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) — DARÉ Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). The award will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1. DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to a 14-day period and is being developed as a treatment for the prevention of preterm birth in at-risk women, for which there are currently no FDA-approved treatments.
“The World Health Organization estimates that globally, 13.4 million babies were born preterm in 2020, before 37 weeks of gestation and that complications from preterm birth are the leading cause of death among children under 5 years of age1,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Daré is committed to addressing persistent unmet needs in women’s health and preterm birth is a large category that could benefit from new treatment options to protect women and babies. We are grateful to the NICHD for its support and commitment to innovation in this important therapeutic area and look forward to advancing DARE-PTB1, which has the potential to be the only FDA-approved product to reduce the risk of preterm birth.”
Daré’s IVR technology is designed to allow for sustained drug delivery over time periods ranging from weeks to months as a self-administered progesterone vaginal system.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?